Evidence Grade D — Primarily preclinical. 10 published studies, mostly animal models. 12 registered clinical trials.
Medically reviewed by a licensed medical professional
Ecnoglutide is a once-weekly GLP-1 treatment developed by Sciwind Biosciences in China, with a unique pharmacological feature: an extreme signalling bias that keeps the GLP-1 receptor available at the cell surface for longer, theoretically sustaining the drug's effect. Phase III trials have shown competitive weight loss results, and a partnership with Pfizer for commercialisation provides significant commercial validation.
Ecnoglutide is also known by these brand and alternate names:
10 published studies: 7 human, 0 animal, 1 in-vitro, 3 reviews
Ecnoglutide is in Phase III development (not yet approved). The SLIMMER Phase III trial (664 patients, 48 weeks) showed 15.4% weight loss at the 2.4 mg dose. A separate Phase III diabetes trial showed HbA1c reduction of 2.43%.
Ecnoglutide's biased agonism profile is its key differentiator within the competitive GLP-1 agonist landscape. Whether the extreme signalling bias translates to meaningful clinical advantages in tolerability or sustained efficacy compared to existing GLP-1 agonists will be determined by ongoing comparative data.
Ecnoglutide activates the GLP-1 receptor with exceptional selectivity for the cAMP signalling pathway while minimally triggering receptor internalisation (the process that normally reduces receptor availability after drug exposure). This biased agonism theoretically maintains receptor sensitivity over time, potentially sustaining drug effect and reducing the dose escalation needed with conventional GLP-1 agonists.
Phase III results (SLIMMER trial, 664 patients) showed 15.4% weight loss at 48 weeks, competitive with semaglutide. The extreme signalling bias (over 500,000-fold preference for one pathway over another) is genuinely novel among GLP-1 drugs. A partnership with Pfizer for Chinese commercialisation provides significant validation. All Phase III data are from Chinese populations only, and no trials outside China are planned. An oral formulation remains at Phase I with limited data. The 15.4% weight loss is competitive but not class-leading in a landscape where newer multi-target drugs are achieving over 20%. Whether the biased signalling translates to meaningful tolerability or durability advantages over conventional GLP-1 drugs remains to be demonstrated.
PeptideTrace tracks 12 registered clinical trials for Ecnoglutide sourced from ClinicalTrials.gov.
A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight
A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Ecnoglutide (XW003) is a long-acting GLP-1(7-37) peptide analog with a Val8 substitution promoting cAMP-biased signaling and C18 diacid fatty acid conjugation at Lys30 for albumin binding. CAS number: 2459531-73-6. Developed by Sciwind Biosciences (Hangzhou, China). The compound uses exclusively natural amino acids, simplifying recombinant manufacturing. Half-life at steady state: 124-138 hours. Ecnoglutide received NMPA approval in China for type 2 diabetes on January 30, 2026, making it the world's first approved cAMP-biased GLP-1 agonist. An obesity NDA is under NMPA review, and Sciwind partnered with Pfizer China in February 2026 for exclusive commercialization rights.
Ecnoglutide demonstrates exceptional signaling bias: cAMP EC50 of 0.018 nM versus receptor internalization EC50 greater than 10 micromolar, representing a greater than 500,000-fold bias toward cAMP signaling over beta-arrestin recruitment. This biased agonism theoretically attenuates receptor desensitization and sustains GLP-1R signaling duration. The Val8 substitution is the key molecular modification responsible for this signaling profile, reducing beta-arrestin-mediated receptor internalization while preserving full Gs-coupled cAMP activation.
SLIMMER Phase 3 (NCT05813795; N=664; Lancet Diabetes and Endocrinology June 2025): the 2.4 mg dose achieved -15.4% weight loss at 48 weeks (placebo-adjusted -15.1%; P<0.0001), with 92.8% achieving at least 5% loss and 79.6% achieving at least 10%. EECOH-1 Phase 3 T2D (NCT05680155; N=211): HbA1c reduction of -2.43% (1.2 mg) versus -0.55% placebo, with 76.1% achieving HbA1c at or below 6.5%. Phase 2b versus liraglutide (N=206): 2.4 mg achieved -14.7% weight loss versus -8.8% for liraglutide (P<0.001). Treatment completion rates were excellent at 92% in SLIMMER.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Semaglutide is one of the most extensively studied peptide medications available today, with clinical trial data spanning over 50,000 patients. It is sold as Ozempic for type 2 diabetes (approved 2017), Rybelsus as an oral tablet for diabetes (approved 2019), and Wegovy for weight management (approved 2021). Wegovy has since received additional approvals for reducing heart attack and stroke risk, for use in adolescents aged 12 and older, and for liver disease related to obesity. In clinical trials, patients taking Wegovy lost an average of 14.9% of their body weight over 68 weeks, and the SELECT trial demonstrated a 20% reduction in major cardiovascular events such as heart attack and stroke. Research is now exploring its potential in early Alzheimer's disease. The main side effects are gastrointestinal, particularly nausea, and a key limitation is that most weight tends to return after stopping treatment.
Bimagrumab is in Phase II/III development (not yet approved). A Phase II trial (75 patients with type 2 diabetes and obesity) showed 20.5% fat mass reduction with 3.6% lean mass increase — essentially reshaping body composition without net appetite suppression. The BELIEVE Phase IIb trial (507 patients) showed that bimagrumab plus semaglutide achieved 22% weight loss with the weight lost being 88% fat — significantly better body composition than semaglutide alone. Bimagrumab is not a peptide. Its strategic significance is as a combination partner to address the muscle loss problem inherent in weight loss with current obesity drugs. Eli Lilly's acquisition positions it alongside tirzepatide.
Pemvidutide is in Phase II/III development (not yet approved). In the MOMENTUM Phase II trial (391 patients, 48 weeks), the 2.4 mg dose achieved 15.6% weight loss. Body composition analysis showed 78% of weight lost was fat mass, with only 22% lean mass — a favourable ratio. A Phase IIb MASH trial (212 patients) showed MASH resolution in up to 75% of patients at the highest dose. Pemvidutide's balanced receptor profile and no-titration dosing regimen represent potential practical advantages. The high rate of MASH resolution in Phase II positions it as a candidate for liver disease indications alongside obesity.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
